Product logins

Find logins to all Clarivate products below.


The drug profile includes the sales and forecast for the time period 2017 – 2028 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of upsides and downsides.
 

Related Market Assessment Reports

Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…
Report
Non-Small-Cell Lung Cancer | China In-Depth | China | 2022
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Report
Rheumatoid Arthritis | Disease Landscape & Forecast | G7 | 2022
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Report
Hemophilia A +/- Inhibitors | Disease Landscape & Forecast | G7 | 2022
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
Report
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2022
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…